193 related articles for article (PubMed ID: 26565002)
1. Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.
Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Rossi FM; Zucchetto A; Rossi D; Bomben R; Maurillo L; Cefalo M; De Santis G; Venditti A; Gaidano G; Amadori S; de Fabritiis P; Gattei V; Del Poeta G
Haematologica; 2016 Jan; 101(1):77-85. PubMed ID: 26565002
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.
Saxena A; Viswanathan S; Moshynska O; Tandon P; Sankaran K; Sheridan DP
Am J Hematol; 2004 Jan; 75(1):22-33. PubMed ID: 14695629
[TBL] [Abstract][Full Text] [Related]
3. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
[TBL] [Abstract][Full Text] [Related]
4. High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
Helaly NA; Esheba NE; Ammo DEA; Elwan NM; Elkholy RA
Leuk Res; 2021 Aug; 107():106604. PubMed ID: 33965850
[TBL] [Abstract][Full Text] [Related]
5. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
6. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
Del Poeta G; Del Principe MI; Zucchetto A; Luciano F; Buccisano F; Rossi FM; Bruno A; Biagi A; Bulian P; Maurillo L; Neri B; Bomben R; Simotti C; Coletta AM; Dal Bo M; de Fabritiis P; Venditti A; Gattei V; Amadori S
Haematologica; 2012 Feb; 97(2):279-87. PubMed ID: 21993667
[TBL] [Abstract][Full Text] [Related]
7. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
9. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
12. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
Del Poeta G; Venditti A; Del Principe MI; Maurillo L; Buccisano F; Tamburini A; Cox MC; Franchi A; Bruno A; Mazzone C; Panetta P; Suppo G; Masi M; Amadori S
Blood; 2003 Mar; 101(6):2125-31. PubMed ID: 12424199
[TBL] [Abstract][Full Text] [Related]
13. [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
Plander M; Skrapits J; Bozsó T; Szendrei T; Iványi JL
Orv Hetil; 2012 Oct; 153(41):1622-8. PubMed ID: 23045312
[TBL] [Abstract][Full Text] [Related]
14. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
[TBL] [Abstract][Full Text] [Related]
15. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
[TBL] [Abstract][Full Text] [Related]
16. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Ayyildiz O; Isikdogan A; Bolaman Z; Muftuoglu E
Saudi Med J; 2004 Dec; 25(12):2054-6. PubMed ID: 15711709
[No Abstract] [Full Text] [Related]
18. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
19. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
Pepper C; Lin TT; Pratt G; Hewamana S; Brennan P; Hiller L; Hills R; Ward R; Starczynski J; Austen B; Hooper L; Stankovic T; Fegan C
Blood; 2008 Nov; 112(9):3807-17. PubMed ID: 18599795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]